Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report issued on Saturday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

NASDAQ:BLPH opened at $0.04 on Friday. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.42. The stock has a fifty day moving average price of $0.04 and a two-hundred day moving average price of $0.05. The stock has a market capitalization of $428,155.00, a price-to-earnings ratio of -0.04 and a beta of 0.70.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.